Genprex Inc

NASDAQ:GNPXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.

Contact Information

Headquarters

1601 Trinity Street Bldg. B, Suite 3.322AUSTIN, TX, United States 78712

Phone

512-537-7997

Fax

302-655-5049

Executives

Independent Chairman of the Board

Jose Moreno Toscano

President, Chief Executive Officer, Chief Financial Officer, Director

Ryan Confer

Chief Medical Officer

Mark Berger

Independent Director

Brent Longnecker

Independent Director

William Wilson